Evidence for the facilitated transport of methotrexate polyglutamates into lysosomes derived from S180 cells. Basic properties and specificity for polyglutamate chain length.
Evidence is presented outlining basic properties of a previously undescribed facilitative transport system mediating transfer of methotrexate (MTX) polyglutamates from the cytoplasmic to the lysosomal compartment of the cell. These experiments were conducted using purified lysosomes prepared from murine S180 cells, and a model substrate ([3H]MTX + G1; methotrexate with 1 additional glutamyl residue) to examine biological aspects as well as pharmacological significance of this process in a tumor cell model. The data, expressed as a function of latent beta-hexosaminidase activity, a measure of lysosomal integrity, show that [3H]MTX + G1 uptake in lysosomes is temperature-dependent, is stimulated specifically by magnesium chloride and potassium chloride with maximal enhancement observed in the presence of both agents together, exhibits Michaelis-Menten saturation kinetics with Km and Vmax values of 346 +/- 39 microM and 2.8 +/- 0.3 pmol/min/unit of beta-hexosaminidase activity, respectively, and is competitively inhibited by longer chain polyglutamates with increasing effectiveness as shown by Ki values of 334 +/- 19, 201 +/- 16, 106 +/- 13, and 42 +/- 8 microM, for MTX + G1, MTX + G2, MTX + G3, and MTX + G4, respectively. In addition, uptake is inversely related to medium osmolarity indicating that the phenomenon we observe represents internalization of the [3H]MTX + G1 and not adsorption to a possible surface binding site. As a whole, the data are consistent with a single mediated transport system shared by all MTX polyglutamates for entry into lysosomes. It is our view that this transport system represents the initial step in the degradation of polyglutamates in the cell. In addition, based on a comparative analysis of the kinetics for hydrolysis and transport, we suggest that it is also the limiting step in this process and, as such, regulates the extent of degradation of the free cellular pools of these compounds.
Barrueco
J R
JR
Laboratory for Molecular Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Sirotnak
F M
FM
D000818:Animals; D001692:Biological Transport; D002412:Cations; D002460:Cell Line; D008247:Lysosomes / Q000378:metabolism*; D008274:Magnesium / Q000378:metabolism; D008727:Methotrexate / Q000031:analogs & derivatives* / Q000378:metabolism; D051379:Mice; D009994:Osmolar Concentration; D011099:Polyglutamic Acid / Q000031:analogs & derivatives* / Q000378:metabolism; D011188:Potassium / Q000378:metabolism; D013379:Substrate Specificity; D014407:Tumor Cells, Cultured; D001619:beta-N-Acetylhexosaminidases / Q000032:analysis
D002412:Cations; D011099:Polyglutamic Acid; C014085:methotrexate polyglutamate; D001619:beta-N-Acetylhexosaminidases; D008274:Magnesium; D011188:Potassium; D008727:Methotrexate